Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours

Histopathology

Volumn 54, Issue 3, 2009, Pages 337-347

  Westgaard, Arne ^a   Schjølberg, Aasa R ^a   Cvancarova, Milada ^a   Eide, Tor J ^a   Clausen, Ole Petter F ^a   Gladhaug, Ivar P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Histological differentiation; Immunohistochemical markers; Intestinal histological type; Pancreatic head adenocarcinoma; Pancreatobiliary histological type

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; MUCIN 1; MUCIN 2; MUCIN 4; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER;

ARTICLE; BILIARY TRACT TUMOR; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INFILTRATION; CANCER SIZE; CELL STRUCTURE; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; INTESTINE TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; VASCULAR DISEASE;

ADENOCARCINOMA; ANTIGENS, DIFFERENTIATION; BILE DUCT NEOPLASMS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; MUCIN-1; MUCIN-4; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 60349092235     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03227.x     Document Type: Article

References (47)

1. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann. Surg. 1998 227 821 831.
2. Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Periampullary cancers: are there differences? Surg. Clin. North Am. 2001 81 543 555.
3. Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, D.C. : Armed Forces Institute of Pathology, 2000.
4. Albores-Saavedra J, Henson DE, Klimstra DS. Malignant epithelial tumors of the ampulla. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, D.C. : Armed Forces Institute of Pathology, 2000 259 316.
5. Kimura W, Futakawa N, Yamagata S et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn. J. Cancer Res. 1994 85 161 166.
6. Hong SM, Cho H, Moskaluk CA, Frierson HF Jr., Yu E, Ro JY. CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. Am. J. Clin. Pathol. 2005 124 361 370.
7. Albores-Saavedra J, Henson DE, Klimstra DS. Dysplasia, carcinoma in situ, and invasive carcinoma of the extrahepatic bile ducts. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, D.C Armed Forces Institute of Pathology, 2000 191 215.
8. Matsumoto K, Mizoshita T, Tsukamoto T et al. Cdx2 expression in pancreatic tumors: relationship with prognosis of invasive ductal carcinomas. Oncol. Rep. 2004 12 1239 1243.
9. Albores-Saavedra J, Simpson K, Dancer YJ, Hruban R. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann. Diagn. Pathol. 2007 11 3 9.
10. Westgaard A, Tafjord S, Farstad IN, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008 8 170.
11. Westgaard A, Tafjord S, Farstad IN et al. Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC. Cancer 2008 8 5.
12. Greene FL (ed.) Ampulla of Vater. In AJCC cancer staging manual. New York : Springer, 2002 151 156.
13. Monson JR, Donohue JH, McEntee GP et al. Radical resection for carcinoma of the ampulla of Vater. Arch. Surg. 1991 126 353 357.
14. Fisher W, Bakey M. Differences between ampullary, periampullary and pancreatic cancer. World J. Surg. 2007 31 144 146.
15. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann. Surg. 1998 228 87 94.
16. Luttges J, Zamboni G, Kloppel G. Recommendation for the examination of pancreaticoduodenectomy specimens removed from patients with carcinoma of the exocrine pancreas. A proposal for a standardized pathological staging of pancreaticoduodenectomy specimens including a checklist. Dig. Surg. 1999 16 291 296.
17. Matsubayashi H, Watanabe H, Yamaguchi T et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of vater. Cancer 1999 86 596 607.
18. Kitamura H, Yonezawa S, Tanaka S, Kim YS, Sato E. Expression of mucin carbohydrates and core proteins in carcinomas of the ampulla of Vater: their relationship to prognosis. Jpn. J. Cancer Res. 1996 87 631 640.
19. Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF Jr. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod. Pathol. 2003 16 913 919.
20. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am. J. Surg. Pathol. 2003 27 303 310.
21. Saitou M, Goto M, Horinouchi M et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J. Clin. Pathol. 2005 58 845 852.
22. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am. J. Surg. Pathol. 2005 29 359 367.
23. Sessa F, Furlan D, Zampatti C, Carnevali I, Franzi F, Capella C. Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch. 2007 451 649 657.
24. Zhou H, Schaefer N, Wolff M, Fischer HP. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am. J. Surg. Pathol. 2004 28 875 882.
25. Hansel DE, Maitra A, Lin JW et al. Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. J. Clin. Oncol. 2005 23 1811 1818.
26. Kaimaktchiev V, Terracciano L, Tornillo L et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod. Pathol. 2004 17 1392 1399.
27. Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat. Rev. Cancer 2003 3 592 600.
28. Chang YT, Hsu C, Jeng YM, Chang MC, Wei SC, Wong JM. Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma. J. Gastroenterol. Hepatol. 2007 22 389 394.
29. Okada T, Masuda N, Fukai Y et al. Immunohistochemical expression of 14-3-3 sigma protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas. Anticancer Res. 2006 26 3105 3110.
30. Bhardwaj A, Marsh WL Jr., Nash JW, Barbacioru CC, Jones S, Frankel WL. Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study. Arch. Pathol. Lab. Med. 2007 131 556 562.
31. Andrianifahanana M, Chauhan SC, Choudhury A et al. MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. Am. J. Gastroenterol. 2006 101 2319 2329.
32. Swartz MJ, Batra SK, Varshney GC et al. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am. J. Clin. Pathol. 2002 117 791 796.
33. Tamada S, Shibahara H, Higashi M et al. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin. Cancer Res. 2006 12 (14 Pt 1) 4257 4264.
34. Buisine MP, Devisme L, Degand P et al. Developmental mucin gene expression in the gastroduodenal tract and accessory digestive glands. II. Duodenum and liver, gallbladder, and pancreas. J. Histochem. Cytochem. 2000 48 1667 1676.
35. Paulsen FP, Varoga D, Paulsen AR, Corfield A, Tsokos M. Prognostic value of mucins in the classification of ampullary carcinomas. Hum. Pathol. 2006 37 160 167.
36. Nilsson O, Karlsson B, Lindholm L, Pettersson A. Development of assays for determination of MUC-1 breast cancer antigen. In Klaptor R ed. Current tumor diagnosis: applications, clinical relevance, research trends. Munich : Zuckschwerdt, 1994 130 133.
37. Gum JR, Byrd JC, Hicks JW, Toribara NW, Lamport DT, Kim YS. Molecular cloning of human intestinal mucin cDNAs. Sequence analysis and evidence for genetic polymorphism. J. Biol. Chem. 1989 264 6480 6487.
38. Zhang J, Perez A, Yasin M et al. Presence of MUC4 in human milk and at the luminal surfaces of blood vessels. J. Cell. Physiol. 2005 204 166 177.
39. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002 40 403 439.
40. Carpelan-Holmstrom M, Nordling S, Pukkala E et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005 54 385 387.
41. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J. Natl Cancer Inst. 1994 86 829 835.
42. Kyzas PA, axa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur. J. Cancer 2007 43 2559 2579.
43. Swierczynski SL, Maitra A, Abraham SC et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum. Pathol. 2004 35 357 366.
44. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG. Recommendations for improved standardization of immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 2007 15 124 133.
45. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008 70 431 457.
46. Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. Annu. Rev. Physiol. 2008 70 459 486.
47. Carraway KL III., Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr. Top. Dev. Biol. 2007 78 1 22.